Trial Profile
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV Vaccine (580299) Co-administrated With a Commercially Available Vaccine in Healthy Female Adolescents
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Hepatitis B vaccine recombinant
- Indications Cervical cancer; Human papillomavirus infections
- Focus Pharmacodynamics; Registrational
- Sponsors GSK
- 15 Mar 2012 Official title amended as reported by European Clinical Trials Database.
- 15 Mar 2012 This trial is recruiting in Netherlands.
- 15 Mar 2012 Planned patient number is 756 according to European Clinical Trials Database